The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

BACKGROUND: End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemos Cerqueira, Tiago, Fartolino Guerrero, Armando, Pérez Fermin, Clara Krystal, Wang, Ricardo, Balbino, Evelin Elfriede, Breeze, Janis L, Gonzalez Mego, Paola, Argentina Silva, Daniele, Omer, Walid Ezzeldin, Vandevelde, Nathalie Monique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107730/
https://www.ncbi.nlm.nih.gov/pubmed/30093367
http://dx.doi.org/10.2196/10516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107730/
https://www.ncbi.nlm.nih.gov/pubmed/30093367
http://dx.doi.org/10.2196/10516

Ejemplares similares